Effect of intermediate alemtuzumab schedule to reduces the incidence of mixed chimerism in hematopoietic cell transplant (HCT) patients with hemophagocytic lymphohistiocytosis (HLH).
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2015
At a glance
- Drugs Alemtuzumab (Primary) ; Fludarabine; Melphalan
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 28 Dec 2015 New trial record